The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment

Glioblastoma is the most common and aggressive brain tumour in adults with a median overall survival of only 14  months after standard therapy with radiation therapy (IR) and temozolomide (TMZ). In a novel mult...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Research Source Type: research